Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared on X:
“New HER2 Targeted Therapy Alert!
Zongertinib (BI 1810631) = Game-changer?
• 71% ORR
• 12.4 mo PFS
• Active in brain metastases
• No ILD
• EGFR-sparing ➔ Less rash, diarrhea!
Direct comparison vs trastuzumab deruxtecan!
Clinical MoA snapshot included!”
Read Also: New Paper Alert: Zongertinib in Previously Treated HER2-Mutant NSCLC. Beamion LUNG-1 Study Results
